The price of TC Biopharm (Holdings) Plc (NASDAQ:TCBP) shares last traded on Wall Street rose 20.59% to $3.69.
Based on available information, 1 analysts follow TC Biopharm (Holdings) Plc (NASDAQ:TCBP). The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $7.28 and a low of $7.28, we find $7.28. Given the previous closing price of $3.06, this indicates a potential upside of 137.91 percent. TCBP stock price is now -23.07% away from the 50-day moving average and -69.09% away from the 200-day moving average. The market capitalization of the company currently stands at $3.36M.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our
5 Best Growth Stocks To Own For 2023.
Sponsored
Among analysts, 0 rate the stock a hold while 1 rate it a buy. Brokers who have rated the stock have averaged $7.28 as their price target over the next twelve months.
.
In other news, Randall Diana Elizabeth, 10% Owner bought 70,000 shares of the company’s stock on Nov 30. The stock was bought for $350,000 at an average price of $5.00. Upon completion of the transaction, the 10% Owner now directly owns 70,000 shares in the company, valued at $0.26 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Nov 30, 10% Owner Randall Kenneth Edward bought 70,000 shares of the business’s stock. A total of $350,000 was incurred on buying the stock at an average price of $5.00. This leaves the insider owning 382,963 shares of the company worth $1.41 million. A total of 36.62% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in TCBP stock. A new stake in TC Biopharm (Holdings) Plc shares was purchased by ARMISTICE CAPITAL, LLC during the first quarter worth $305,000. UBS GROUP AG invested $5,000 in shares of TCBP during the first quarter. In total, there are 6 active investors with 12.40% ownership of the company’s stock.
A candlestick chart of TC Biopharm (Holdings) Plc (NASDAQ: TCBP) showed a price of $3.2100 on Wednesday morning. During the past 12 months, TC Biopharm (Holdings) Plc has had a low of $2.81 and a high of $106.50. As of last week, the company has a debt-to-equity ratio of 3.33, a current ratio of 1.10, and a quick ratio of 1.10. The fifty day moving average price for TCBP is $4.7934 and a two-hundred day moving average price translates $11.7397 for the stock.
The latest earnings results from TC Biopharm (Holdings) Plc (NASDAQ: TCBP) was released for Jun, 2022.
TC Biopharm (Holdings) Plc(TCBP) Company Profile
TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on developing immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an unmodified cell therapy used in the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat COVID-19. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom.
